IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 15, 2026
Braveheart Bio, Inc.
Braveheart Bio is a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases.
Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non‑obstructive HCM.
Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 15, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 8, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Apr 29, 2026 | [Cover] Draft Registration Statement |
Contact and headquarters details
Key executives and officers
Travis Murdoch, M.D.
Chief Executive Officer, President and Director
Michele Anderson
Chief Development Officer
J. Paul Rickey
Chief Financial Officer
Tyler Chavez
Chief Business Officer
Marc Evanchik, M.S.
Chief Scientific Officer
Emil deGoma
Chief Medical Officer
Christopher Viehbacher
Chairman of the Board
Vineeta Agarwala, M.D., Ph.D.
Director
Jasper Bos, Ph.D.
Director
Erez Chimovits, M.B.A., M.Sc.
Director